StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) shareholders

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.0%
0M of 1.08B shares
Institutional holders
1
0 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $34.68K

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ELTPValueChange% of portfolio
Wall Street Access Asset Management, LLC1,0000.00%$365+5000.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610M0.0%0 / 10 / 00M0M
Q1 202610M0.0%0 / 00 / 00M0M
Q4 202510M0.0%0 / 00 / 10M0M
Q3 202520M0.0%1 / 00 / 00M0M
Q2 202510M0.0%0 / 00 / 00M0M
Q1 202510M0.0%1 / 00 / 00M0M
Q4 202300M0.0%0 / 00 / 10M0M
Q3 202310M0.0%1 / 00 / 00M0M
Q2 202300M0.0%0 / 00 / 10M0M
Q1 202310M0.0%1 / 00 / 00M0M
Q4 202200M0.0%0 / 00 / 20M1M
Q3 202221M0.1%0 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Douglas PlasscheEVP Operations6,000,0000.56%Jan 13, 2026
Pharmaceuticals Inc /Nv/ EliteEVP Operations4,300,0000.40%Aug 26, 2025
Kirko KirkovChief Commercial Officer16,3660.00%Jul 25, 2025
Aqeel Ahmad FatmiDirector––Nov 9, 2026
John LaRoccaDirector88,5340.01%Nov 6, 2026
Barry H. DashDirector3,365,5550.31%Oct 19, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Barry H. Dash
Director
Oct 9, 2026Buy+100,000$0.26$25.98K3,365,555
Barry H. Dash
Director
Aug 19, 2026Buy+30,000$0.29$8.70K3,265,555
Douglas Plassche
EVP Operations
Jan 9, 2026Option exercise+2,500,000$0.03$75.00K6,000,000
Douglas Plassche
EVP Operations
Oct 2, 2025Sale−800,000$0.62$496.00K3,500,000
Pharmaceuticals Inc /Nv/ Elite
EVP Operations
Aug 25, 2025Option exercise+2,500,000$0.03$75.00K4,300,000
Pharmaceuticals Inc /Nv/ Elite
EVP Operations
Aug 22, 2025Sale−500,000$0.52$260.00K1,800,000
Kirko Kirkov
Chief Commercial Officer
Jul 10, 2025Buy+16,366$0.59$9.66K16,366
Douglas Plassche
EVP Operations
Jul 8, 2025Sale−200,000$0.58$116.00K2,300,000
Douglas Plassche
EVP Operations
Jul 3, 2025Option exercise+2,500,000$0.03$75.00K2,500,000
Douglas Plassche
SVP of Operations
Oct 24, 2024Sale−333,932$0.51$170.31K0
Douglas Plassche
SVP of Operations
Oct 23, 2024Sale−800,000$0.49$392.00K333,932
Nasrat A. Hakim
CEO, President, Director, 10% owner
Mar 29, 2024Award+49,534,368––216,649,250
Nasrat A. Hakim
CEO, President, Director, 10% owner
Dec 29, 2023Award+2,223,147$0.07$155.62K2,223,147
Davis S. Caskey
Director
Nov 22, 2023Award+547,657$0.04$21.91K2,049,436
Barry H. Dash
Director
Nov 22, 2023Award+547,657$0.04$21.91K3,235,555
Jeffrey A. Whitnell
Director
Nov 22, 2023Award+547,657$0.04$21.91K3,187,020
Barry H. Dash
Director
Aug 28, 2022Award+459,536$0.04$18.38K2,687,898
Davis S. Caskey
Director
Aug 28, 2022Award+459,536$0.04$18.38K1,501,779
Jeffrey A. Whitnell
Director
Aug 28, 2022Award+459,536$0.04$18.38K2,639,363
Davis S. Caskey
Director
Jun 30, 2021Award+295,570$0.07$20.69K1,042,243
Jeffrey A. Whitnell
Director
Jun 30, 2021Award+295,570$0.07$20.69K2,179,827
Barry H. Dash
Director
Jun 30, 2021Award+295,570$0.07$20.69K2,228,182
Nasrat A. Hakim
CEO & President, Director, 10% owner
Aug 24, 2020Conversion+158,017,321––167,114,882
Barry H. Dash
Director
Aug 20, 2020Award+516,781$0.09$46.51K1,932,612
Jeffrey A. Whitnell
Director
Aug 20, 2020Award+516,781$0.09$46.51K1,884,257
Davis S. Caskey
Director
Aug 20, 2020Award+516,781$0.09$46.51K746,673
Douglas Plassche
SVP Operations
Aug 20, 2020Award+71,739$0.09$6.46K1,133,932
Douglas Plassche
SVP of Operations
Jun 30, 2020Award+574,597$0.09$51.71K1,062,193
Carter Julian Ward
CFO, Sec., Treas.
Feb 26, 2018Award+242,060$0.12$29.05K2,127,364
Jeffrey A. Whitnell
Director
Feb 26, 2018Award+161,374$0.12$19.36K1,367,476
Davis S. Caskey
Director
Feb 26, 2018Award+161,374$0.12$19.36K229,892
Barry H. Dash
Director
Feb 26, 2018Award+161,374$0.12$19.36K1,415,831
Eugene M. Pfeifer
Director
Feb 26, 2018Award+161,374$0.12$19.36K233,414
Douglas Plassche
SVP of Operations
Feb 26, 2018Award+201,717$0.12$24.21K487,596
Nasrat A. Hakim
CEO & President, Director, 10% owner
Apr 28, 2017Other−158,017,321––9,097,561
Davis S. Caskey
Director
Feb 23, 2017Award+68,518$0.20$13.70K68,518
Nasrat A. Hakim
CEO & President, Director, 10% owner
Feb 23, 2017Award+2,216,992$0.23$509.91K24,143,785
Jeffrey A. Whitnell
Director
Feb 23, 2017Award+88,679$0.23$20.40K1,206,102
Carter Julian Ward
Director
Feb 23, 2017Award+133,019$0.23$30.59K1,885,304
Barry H. Dash
Director
Feb 23, 2017Award+88,679$0.23$20.40K1,254,457
Eugene M. Pfeifer
Director
Feb 23, 2017Award+72,040$0.20$14.41K72,040
Douglas Plassche
SVP of Operations
Feb 23, 2017Award+110,849$0.23$25.50K285,879
Nasrat A. Hakim
CEO & President, Director, 10% owner
Aug 17, 2016Option exercise+142,857,143––142,971,097
Carter Julian Ward
CFO, Secretary, Treasurer
Apr 28, 2016Conversion+666,667$0.06$40.00K1,752,285
Jeenarine Narine
–
Apr 13, 2016Conversion+4,000,000$0.06$240.00K16,742,395
Jerry Treppel
–
Mar 18, 2016Sale−258,090$0.34$87.75K7,640,561
Jerry Treppel
–
Mar 17, 2016Sale−312,430$0.35$109.35K7,898,651
Jerry Treppel
–
Feb 24, 2016Sale−100,456$0.31$31.14K8,211,081
Jerry Treppel
–
Feb 22, 2016Sale−100,000$0.32$32.00K8,311,537
Jerry Treppel
–
Feb 17, 2016Sale−50,000$0.31$15.50K8,411,537
Jeffrey A. Whitnell
Director
Feb 16, 2016Award+81,549$0.25$20.39K1,117,423
Carter Julian Ward
CFO, Sec., Treas
Feb 16, 2016Award+122,325$0.25$30.58K1,085,618
Nasrat A. Hakim
Chairman, CEO, President, Director, 10% owner
Feb 16, 2016Award+2,854,279$0.25$713.57K22,040,747
Jerry Treppel
–
Feb 16, 2016Award+124,646$0.25$31.16K8,461,537
Barry H. Dash
Director
Feb 16, 2016Award+81,549$0.25$20.39K1,165,778
Jeenarine Narine
Director
Feb 16, 2016Award+81,549$0.25$20.39K12,742,395
Douglas Plassche
Exec Vice Pres Operations
Feb 16, 2016Award+47,767$0.26$12.42K175,030
Jerry Treppel
–
Feb 5, 2016Sale−24,400$0.33$8.05K8,336,891
Jerry Treppel
–
Feb 4, 2016Sale−349,660$0.32$111.89K8,361,291
Jerry Treppel
–
Feb 3, 2016Sale−45,518$0.33$15.02K8,710,951

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
3M shares short
Days to cover
2.8
At 1M shares a day
Change since last report
-1.4%
From 3M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Elite Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Douglas Plassche
Officer
Aug 22, 2025100,000$555.00KAug 22, 2025Stock Options Exercise
Douglas Plassche
Officer
Jul 8, 2025500,000$303.00KJul 8, 2025Stock Options Exercise
Douglas Plassche
Officer
Oct 23, 20241,133,932$680.36KOct 23, 2024Payment for Services Rendered

See a number that looks wrong?